Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

TRIANGLE PHARMACEUTICALS INC Form 8-K December 07, 2001

> OMB APPROVAL OMB Number: 3235-0060 Expires: May 31, 2000 Estimated average burden hours per response.....5.00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 30, 2001

TRIANGLE PHARMACEUTICALS, INC.

 (Exact name of registrant as specified in its charter)

 DELAWARE
 000-21589
 56-1930728

 (State or other jurisdiction (Commission (IRS Employer of incorporation)
 File Number)
 Identification No.)

 4 University Place, 4611 University Drive, Durham, North Carolina 27707
 (Address of principal executive offices) (Zip Code)

 Registrant's telephone number, including area code (919) 493-5980
 (Pormer name or former address, if changed since last report)

Item 5. Other Events.

On November 30, 2001, Triangle Pharmaceuticals entered into a Master Loan and Security Agreement with Wells Fargo Equipment Finance, Inc., a copy of

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

which is attached hereto as Exhibit 10.1. and is incorporated herein by reference

- Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
- (c) Exhibits. The following documents are filed as exhibits to this Report:
- 10.1 Master Loan and Security Agreement dated November 30, 2001 between Triangle Pharmaceuticals, Inc. and Wells Fargo Equipment Finance, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Triangle Pharmaceuticals, Inc.

(Registrant)

December 7, 2001

/s/ Robert F. Amundsen, Jr.

Date

(Signature) Name: Robert F. Amundsen, Jr. Title: Executive Vice President & Chief Financial Officer